Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Cash from Operations (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Cash from Operations for 4 consecutive years, with 58312000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Operations fell 172.63% to 58312000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was 180810000.0, a 38.76% decrease, with the full-year FY2024 number at 142055000.0, up 11.4% from a year prior.
  • Cash from Operations was 58312000.0 for Q3 2025 at Centessa Pharmaceuticals, down from 22452000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 21389000.0 in Q3 2024 to a low of 59877000.0 in Q2 2022.
  • A 4-year average of 42730200.0 and a median of 42800000.0 in 2024 define the central range for Cash from Operations.
  • Biggest YoY gain for Cash from Operations was 44.67% in 2025; the steepest drop was 172.63% in 2025.
  • Centessa Pharmaceuticals' Cash from Operations stood at 51564000.0 in 2022, then soared by 39.78% to 31050000.0 in 2023, then plummeted by 37.84% to 42800000.0 in 2024, then tumbled by 36.24% to 58312000.0 in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Cash from Operations are 58312000.0 (Q3 2025), 22452000.0 (Q2 2025), and 57246000.0 (Q1 2025).